The apolipoprotein B messenger RNA editing enzyme, catalytic polypeptide-like (APOBEC) family of single-stranded DNA (ssDNA) cytosine deaminases provides innate immunity against virus and transposon replication 1-4 . A well-studied mechanism is APOBEC3G restriction of human immunodeficiency virus type 1, which is counteracted by a virus-encoded degradation mechanism 1-4 . Accordingly, most work has focused on retroviruses with obligate ssDNA replication intermediates and it is unclear whether large double-stranded DNA (dsDNA) viruses may be similarly susceptible to restriction. Here, we show that the large dsDNA herpesvirus Epstein-Barr virus (EBV), which is the causative agent of infectious mononucleosis and multiple cancers 5 , utilizes a two-pronged approach to counteract restriction by APOBEC3B. Proteomics studies and immunoprecipitation experiments showed that the ribonucleotide reductase large subunit of EBV, BORF2 6,7 , binds APOBEC3B. Mutagenesis mapped the interaction to the APOBEC3B catalytic domain, and biochemical studies demonstrated that BORF2 stoichiometrically inhibits APOBEC3B DNA cytosine deaminase activity. BORF2 also caused a dramatic relocalization of nuclear APOBEC3B to perinuclear bodies. On lytic reactivation, BORF2-null viruses were susceptible to APOBEC3B-mediated deamination as evidenced by lower viral titres, lower infectivity and hypermutation. The Kaposi's sarcoma-associated herpesvirus homologue, ORF61, also bound APOBEC3B and mediated relocalization. These data support a model where the genomic integrity of human γ-herpesviruses is maintained by active neutralization of the antiviral enzyme APOBEC3B.
). Co-immunoprecipitation experiments confirmed that BORF2-FLAG binds endogenous A3B in HEK293T cells as well as in AGS gastric adenocarcinoma cells, an established model for EBV studies (for example, see Kraus et al. 8 , Hagemeier et al. 9 and Verma et al. 10 ; Fig. 1b and Supplementary Fig. 1c,d ). Mechanistic conservation was indicated by similarly strong interaction with the large ribonucleotide reductase subunit from Kaposi's sarcoma-associated herpesvirus (KSHV), ORF61, and undetectable interactions with homologous proteins from more distantly related herpesviruses (herpes simplex virus type 1 (HSV-1) UL39 and human cytomegalovirus (HCMV) UL45) or human ribonucleoside-diphosphate reductase large subunit (RRM1) ( Supplementary Fig. 2a ). In addition, a BORF2 deletion analysis mapped the A3B interaction to the conserved core RNR domain, and showed that the required region is more extensive than that needed for interaction with the EBV RNR small subunit, BaRF1 ( Supplementary Fig. 3a-d ). Furthermore, BORF2 catalytic residues were dispensable for interacting with A3B, suggesting an RNR-independent function ( Supplementary Fig. 3e ).
Interaction specificity was further evidenced by comparisons with related APOBEC family members, which revealed a prominent interaction with A3B-HA, barely detectable interactions with A3A-HA and A3F-HA, and undetectable interactions with A3C-HA, A3D-HA, A3G-HA, and A3H-HA ( Fig. 1c and Supplementary  Fig. 4 ). The interaction mapped to the A3B C-terminal domain via co-immunoprecipitation experiments using BORF2-FLAG and individually expressed hemagglutinin (HA)-tagged N-and C-terminal domains (ntd, ctd) ( Fig. 1d ). Additional co-immunoprecipitation experiments using chimeras of A3B and A3G (A3Bntd-A3Gctd or A3Gntd-A3Bctd) confirmed the C-terminal specificity of this interaction (Fig. 1e ). A3Bctd and A3Gctd belong to the same deaminase subgroup 11 and the majority of amino acid differences are confined to surface-exposed regions; this enabled the construction of a series of chimeras with exchanged loop regions. The BORF2 interaction was abolished using an A3B construct with loop 7 (L7) from A3G and, conversely, it was enabled using an A3G construct with L7 from A3B (Fig. 1f ). These data indicated that BORF2 interacts preferentially with A3Bctd and specifically with a region involving L7 residues.
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Recent structural studies have shown that A3Bctd L7 is essential for binding to 5′ -TC containing ssDNA substrates 12 . The specificity of the BORF2 interaction with the L7 region of A3B suggested that BORF2 may function by directly inhibiting ssDNA deaminase activity. To test this mechanism, recombinant BORF2 and A3Bctd were purified from Escherichia coli and used in a series of in vitro ssDNA deaminase assays ( Fig. 2a and Supplementary Fig. 5 ). The related enzyme, A3H, which also prefers 5′ -TC ssDNA substrates 13 and does not interact with BORF2 (see earlier), was purified and tested in parallel as a negative control. A clear dose-dependent inhibition of A3Bctd catalytic activity, approaching near complete inhibition at equimolar concentrations, was observed in multiple independent BORF2 titration experiments (P = 2.7 × 10 −5 , onetailed one sample t-test; Fig. 2b,c) . In comparison, BORF2 had no significant effect on A3H enzymatic activity even at eightfold molar excess concentrations (P = 0.1575, one-tailed one sample t-test). These results demonstrated that an alternative function of BORF2 is specific inhibition of A3B catalytic activity and that other viral (for example, BaRF1) or cellular factors are not required for this activity.
The archetypal mechanism for virus-mediated neutralization of APOBEC3 enzymes is target engagement followed by polyubiquitination and proteasomal degradation [1] [2] [3] [4] . In contrast, BORF2 expression stabilizes steady-state levels of cellular A3B, suggesting a degradation-independent mechanism (Fig. 3a) . In support, proteasome inhibition by MG132 had little effect on cellular A3B levels with or without BORF2 ( Supplementary Fig. 6 ). To gain further insights into this unique mechanism and to assess the interaction of these proteins in the context of EBV lytic replication, immunofluorescence microscopy was used to examine the subcellular localization of endogenous A3B and BORF2 produced after reactivation of AGS cells latently infected with EBV (AGS-EBV) 14, 15 . A3B was predominantly pan-nuclear in latent AGS-EBV cells before reactivation (Fig. 3b, upper panel) , consistent with prior reports for A3B localization in a variety of non-infected cell types (for example, see Bogerd et al. 16 and Burns et al. 17 ). After reactivation to the lytic cycle, nuclear and perinuclear bodies containing both A3B and BORF2 accumulated rapidly and, as the lytic phase progressed, additional cytoplasmic bodies containing BORF2 and A3B increased in abundance (Fig. 3b, bottom panels, and Fig. 3c ). Additional imaging Fig. 1 | EBV BORF2 interacts with cellular A3B. a, Total spectral counts from three independent affinity purification-mass spectrometry experiments using transfected BORF2-FLAG as bait and empty FLAG vector as negative control in HEK293T cells. b, Co-immunoprecipitation of endogenous A3B in HEK293T and AGS cells with BORF2-FLAG, RRM1-FLAG, or an empty vector control. c-f, Co-immunoprecipitation of indicated HA-tagged A3 constructs in HEK293T cells with BORF2-FLAG. Immunoblot labels (b-f) are provided in kDa. These data (a-f) are each representative of at least n = 3 biologically independent experiments.
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NATuRE MICROBIOlOGy studies with markers for cytoplasmic organelles indicated that the BORF2/A3B bodies accumulated within the endoplasmic reticulum ( Fig. 3d ). In particular, three-dimensional reconstructions of image z-stacks showed that these aggregates are surrounded on all sides by the integral endoplasmic reticulum component binding immunoglobulin protein (BiP)/GRP-78 (Supplementary Video 1). A similar result was obtained in reactivated AGS-EBV cells using a second endoplasmic reticulum marker, translocon-associated protein α subunit (TRAPα ; Supplementary Video 2). BORF2 alone also caused A3B relocalization in other cell types, including U2OS, HeLa, HEK293T, and AGS cells ( Fig. 3d ,e, Supplementary Fig. 7 and Supplementary Videos 3 and 4). In addition, relocalization of endogenous A3B and colocalization with BORF2 was observed in M81 EBV-transformed B cells that spontaneously enter the lytic cycle 18 ( Fig. 3f and Supplementary Fig. 7g ,h). Importantly, ORF61 of KSHV also sequestered A3B in perinuclear and cytoplasmic bodies, further indicating mechanistic conservation ( Supplementary Fig. 2b,c) .
To directly test whether A3B relocalization is dependent on BORF2, CRISPR-Cas9 was used to disrupt the BORF2 gene in AGS-EBV cells and in AGS cells containing GFP-tagged viral genomes (AGS-EBV(Bx1g) 15, 19 ; Supplementary Fig. 8a ). Despite numerous EBV genome copies in these cells, a near complete ablation of BORF2 expression was achieved as evidenced by immunoblotting and by sequencing the DNA region targeted by Cas9-gRNA complexes ( Supplementary Fig. 8b ,c). BORF2 knockout viruses were then reactivated to the lytic cycle, and cells containing lytic replicating EBV were identified by staining for the EBV DNA polymerase processivity factor BMRF1 and for new viral DNA synthesis by 5-ethynyl-2′ -deoxyuridine (EdU) incorporation. In these cells, perinuclear and cytoplasmic A3B bodies were not observed, indicating that A3B relocalization from the nucleus is completely dependent on BORF2 (Fig. 3g ). In addition, a proportion of A3B colocalized with BMRF1 and EdU indicating that A3B associates with viral DNA replication intermediates in the absence of BORF2.
Our findings that BORF2 directly inhibits and relocalizes A3B away from viral replication centres strongly suggested that this DNA cytosine deaminase could be a threat to EBV genomic integrity.
Based on the hallmark DNA deamination activity of A3B, we hypothesized that viral ssDNA replication intermediates would become susceptible to A3B-catalysed DNA cytosine deamination in the absence of BORF2. To test this possibility, we analysed viral genomic DNA C/G-to-T/A hypermutation by sequencing individual differential DNA denaturation (three-dimensional (3D))-PCR products representing multiple regions of the viral genome. 3D-PCR estimates the lowest denaturation temperature required for amplification of any DNA substrate; thereby, it enables recovery of C/G-to-T/A hypermutated sequences by virtue of preferential amplification at lower than wild-type (WT) DNA denaturation temperatures 20, 21 (Fig. 4a ). Indeed, in a series of pilot experiments, a segment of the BRRF2 gene was amplified at lower denaturation temperatures from reactivated AGS-EBV cells containing BORF2null EBV genomes compared to cells containing WT EBV genomes ( Supplementary Fig. 9a ). Low temperature amplicons were not recovered from latently infected cell pools (before reactivation). Cloning and sequencing of individual PCR products revealed the highest level of mutation in amplicons from lytic, replicationinduced, BORF2-null conditions ( Supplementary Fig. 9b ).
We next generated a clonal system to extend these studies. Viruscontaining supernatants from pooled AGS-EBV(Bx1g) cells with BORF2-null EBV were harvested and used to infect new parental AGS cells. A clonal AGS cell line with a single isogenic BORF2null EBV was generated (AGS-EBV(Bx1g)∆ BORF2). These cells were first stably complemented with control or BORF2-FLAGexpressing lentivirus. Second, they were transduced with short hairpin RNA (shRNA) to knockdown endogenous A3B or with a non-targeting control (Fig. 4b ). Third, a control vector or uracil glycosylase inhibitor (UGI) was added by transduction of cells from each condition to inhibit the repair of A3B-mediated uracil lesions and potentially exacerbate the effects of A3B-mediated viral hypermutation. UGI uses a structurally conserved mechanism to inhibit uracil DNA glycosylases (UDGs) across kingdoms, including bacterial, human, and EBV enzymes 22, 23 (Supplementary Fig. 10 ). Cells from each of these 8 conditions were cultured to maintain EBV latency (uninduced) or treated with 12-O-tetradecanoylphorbol-13-acetate (TPA) and sodium butyrate for 48 h to reactivate EBV 
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lytic replication (induced); then, DNA was collected and mutations were analysed by sequencing individual 3D-PCR products. Under normal cell culture conditions that maintain EBV latency, low temperature BRRF2 amplicons were rarely observed for any of the eight conditions ( Fig. 4c) . Similarly, BORF2-complemented cells, regardless of cell culture treatments or other genetic manipulations, did not yield lower-temperature BRRF2 PCR amplicons. In contrast, after induction of EBV lytic replication, lower-temperature PCR amplicons could be generated from AGS-EBV(Bx1g)∆ BORF2 cells expressing endogenous levels of A3B, and this phenotype was exacerbated by UGI treatment. The accumulation of lower-temperature amplicons was completely dependent on A3B activity since no lower-temperature BRRF2 amplicons were recovered from A3B knockdown cells that were otherwise treated identically. Similar results were obtained by 3D-PCR analysis of a region of Epstein-Barr virus nuclear antigen 2 (EBNA2; Supplementary Fig. 9c ).
A sequence analysis of individual 3D-PCR products confirmed these results, showing extensive mutagenesis of BRRF2 sequences from AGS-EBV(Bx1g)∆ BORF2 cells expressing endogenous A3B, both with and without UGI treatment ( Fig. 4d and Supplementary  Figs. 11a and 12 ). Interestingly, diverse mutational events were observed, including strong enrichments for C/G-to-T/A mutations and deletions. A high deletion frequency was unexpected and, based on precedents with activation-induced deaminase in antibody . Parallel quantification of A3B localization in lytic BORF2-null AGS-EBV cells (24 h; n = 50 cells). d, Representative immunofluorescence microscopy images of U2OS expressing A3B-mCherry and BORF2-eGFP, and stained with an antibody against the endoplasmic reticulum protein, BiP/GRP-78 (purple; also see Supplementary Video 1). e, Representative immunofluorescence microscopy images of HeLa cells transiently expressing A3B-eGFP alone, BORF2-FLAG alone, or both proteins together. f, Representative immunofluorescence microscopy images of endogenous A3B (green) and BORF2 (red) in a M81-transformed B cell that has spontaneously entered the lytic cycle. g, Representative immunofluorescence microscopy images of endogenous A3B (green) in AGS-EBV and ∆ BORF2 derivative pools 24 h after lytic reactivation. Anti-DNA polymerase processivity factor BMRF1 (purple) marks sites of viral DNA replication in lytic cells and EdU (red) shows newly synthesized DNA. These data are representative of n = 2 (a,d,f,g) or n = 3 (b,c,e,f) biologically independent experiments. Scale bars (b,d-g), 10 μ m.
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diversification 24, 25 , probably due to processing of A3B-induced lesions by cellular DNA damage response mechanisms. This is supported by a trend towards more deletions without UGI, since uracil excision can readily lead to single-stranded nicks and broken DNA. However, A3B-attributable hypermutation was not observed in Sanger sequences of > 20 high-temperature BRRF2 amplicons from BORF-null conditions ( Supplementary Fig. 11b ), but enrichments for mutations in A3B-preferred 5′ -TCA/T motifs 17 were apparent by deep-sequencing high-temperature amplicons representing four different viral genomic DNA regions ( Fig. 4e ). Therefore, we α-Tub Cell lysates 
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inferred that the hypermutation frequency is relatively low for a given region of EBV. This may be explained by low reactivation rates and by a viral DNA replication mechanism that may only periodically expose ssDNA to deamination by A3B. The potential for this viral DNA hypermutation mechanism to exert a multiplicative effect is supported by BORF2-null viruses showing 60-70% lower titres and, even on titre normalization, a further 50-60% less infectivity after one round of lytic replication in AGS-EBV(Bx1g) cells ( Fig. 4f,g) . Specific knockdown of endogenous A3B resulted in a near-full restoration of viral infectivity ( Fig. 4h) . A dependence on A3B is further evidenced by Akata cells, which we found are homozygous for a 29.5 kb deletion spanning the entire A3B gene 26 , producing BORF2-null and WT viruses with similar titres and infectivity ( Supplementary  Fig. 13 ). Combined, these hypermutation and infectivity results indicated that BORF2 is dispensable during EBV latency, but required to protect viral DNA from A3B mutagenesis during conditions of induced lytic replication.
The A3B neutralization mechanism described here for γ -herpesvirus proteins, EBV BORF2, and KSHV ORF61, is fundamentally different than the A3 degradation mechanism used by lentiviral Vif proteins [1] [2] [3] [4] . In addition to the stark differences of direct inhibition and relocalization versus proteasomal degradation, the replication cycles of EBV and KSHV may be fundamentally less tolerant of APOBEC mutagenesis. This inference is supported by bioinformatics analyses of all sequenced EBV isolates indicating that BORF2 is under negative selection and that the domain of BORF2 that binds A3B contains few non-synonymous mutations ( Supplementary  Fig. 14a-c) . APOBEC-hypermutated sequences are also absent from databases. (Only one prior publication detected hypermutation in EBV by 3D-PCR and implicated a different APOBEC family member 27 .) Nevertheless, A3B-preferred 5′ -TCA deamination substrate motifs are depleted from EBV genomes and, correspondingly, 5′ -TTA product motifs are enriched, consistent with periodic A3Bcatalysed mutation events (despite BORF2) and long-term evolutionary pressure ( Supplementary Fig. 14e ).
In comparison to EBV, KSHV, and related large DNA viruses with low mutation rates 28 , retroviruses have much higher mutation rates and frequent scars from APOBEC mutagenesis 29, 30 (for example, ~10% of patient samples contain human immunodeficiency virus type 1 (HIV-1) sequences with APOBEC signature hypermutations). This mechanistic difference may be due, at least partly, to γ -herpesviruses using a coordinated leading/lagging strand replication mechanism to copy viral dsDNA, whereas HIV-1 uses reverse transcription to copy genomic RNA into an obligate single-stranded complementary DNA (cDNA) intermediate before conversion into dsDNA for integration into the host genome. Therefore, EBV and KSHV may have fewer exposed ssDNA replication intermediates during the lytic phase that can be attacked by A3B. Thus, although the frequency of BORF2-null EBV hypermutation is lower than that documented for Vif-null HIV-1, the overall effect has the potential to be similarly catastrophic because even localized hypermutation could inactivate an essential viral gene or trigger degradation of the full episome. Furthermore, cumulative viral DNA deamination over the lifespan of an infected cell is likely to lead to depletion and potentially even clearance of viral episomes. Disrupting the BORF2/ A3B and ORF61/A3B interactions in vivo may have merit for compromising the genetic integrity of EBV and KSHV, thereby limiting lytic infection that induces infectious mononucleosis and contributes to EBV-and KSHV-driven tumours.
Methods
DNA constructs for expression in human cell lines.
The full set of pcDNA3.1(+ ) human APOBEC-HA expression constructs has been described 31 (A3A (GenBank accession number: NM_145699); A3B (NM_004900); A3C (NM_014508); A3D (NM_152426); A3F (NM_145298); A3G (NM021822); A3H (haplotype II; FJ376615)). A3Bntd , A3Bctd 191-382 , A3Bntd-A3Gctd, and A3Gntd-A3Bctd constructs were cloned by overlap extension PCR as described 32 . The HIV-1 IIIB Vif-Myc construct was also described previously 33 . A3B and A3G L7 swaps were generated by overlap extension PCR on A3B-HA and A3G-HA constructs with primers introducing mutations in L7 to generate the reciprocal amino acid sequence (A3B GL7 YDPLYK(132-137)DQGRCQ and A3G BL7 DQGRCQ(132-137)YDPLYK ). The primers used for A3B GL7 were RSH5336 5′ -TAC GAC CCC CTA TAT AAG GAG GGG CTG CGC ACC CT-3′ and RSH5337 5′ -CTT ATA TAG GGG GTC GTA ATC ATA GAT GCG GGC-3′ ; the primers used for A3G BL7 were RSH5338 5′ -GAT CAA GGA AGA TGT CAG GAG GCG CTG CAA ATG C-3′ and RSH5339 5′ -CTG ACA TCT TCC TTG ATC ATC ATA GAT GCG GGC-3′ . A3B with a C-terminal 2 × Strep-tag (WSHPQFEK) was subcloned using high-fidelity PCR from pcDNA3.1(+ )-A3B-3xHA using primers 5′ -NNA AGC TTA TGA ATC CAC AGA TCA GA-3′ and 5′ -NNG CGG CCG CCC GTT TCC CTG ATT CTG GA-3′ . PCR products were digested with HindIII-HF (New England Biolabs) and NotI-HF (New England Biolabs) and ligated into pcDNA4/TO (Thermo Fisher Scientific) with a C-terminal 2 × Strep-tag. Tetracycline-inducible A3B with a C-terminal mCherry tag was cloned using high-fidelity PCR of previously described A3B-mCherry 34 using primers RSH7018 5′ -NNN NNA AGC TTA CCA CCA TGA ATC CA-3′ and RSH7016 5′ -AGA GTC GCG GCC GCT TAC TTG TAC A-3′ . PCR products were digested with HindIII-HF and NotI-HF and ligated into similarly digested pcDNA5/TO (Thermo Fisher Scientific). The A3B-enhanced green fluorescent protein (eGFP) construct has been described 34 . The pLKO construct expressing an A3B-specific shRNA has been described and validated 17, [35] [36] [37] ; the construct used here has a blasticidin resistance gene in place of the puromycin resistance gene. The pLKO construct expressing a non-targeting shRNA control 38 (5′ -CCT AAG GTT AAG TCG CCC TCG-3′ ) was a gift from Keith Mostov (Addgene plasmid).
BORF2 (GenBank accession number: V01555.2) with a C-terminal 3 × FLAG-tag (DYKDDDDK) was subcloned using high-fidelity PCR from the previously described PMZS3F-BORF2 39 using primers RSH12971 5′ -NNN NGA TAT CGC CGA CAC CAT GGC AAC GAC C-3′ and RSH12848 5′ -NNN NGC GGC CGC CCT TGG CAA GAT TCA CAG GC-3′ . PCR products were digested with EcoRV-HF (New England Biolabs) and NotI-HF and ligated into pcDNA4 (Thermo Fisher Scientific) with a C-terminal 3 × FLAG 40 . BORF2 with a C-terminal eGFP tag was generated using high-fidelity PCR of pcDNA4-BORF2-3 × FLAG using primers RSH13422 5′ -NNN NAT GCA TCA TGG CAA CGA CCA GTC ATG TC-3′ and RSH13424 5′ -NNN NAC GCG TCC TTG GCA AGA TTC ACA GGC TCG-3′ . PCR products were digested with NsiI-HF (New England Biolabs) and MluI-HF (New England Biolabs) and cloned into the previously described pQCXIP (Clontech) with a C-terminal eGFP tag 41 . BORF2 with a C-terminal 3 × FLAG-tag was cloned into a murine leukaemia virus (MLV)based pQCXIP lentivirus vector (Clontech) for complementation experiments by PCR of pcDNA4-BORF2-3 × FLAG using primers RSH13422 5′ -NNN NAT GCA TCA TGG CAA CGA CCA GTC ATG TC-3′ and RSH13423 5′ -NNN NTT AAT TAA TTA AAC GGG CCC CTT GTC GTC-3′ . The PCR product was digested into NsiI-HF and PacI (New England Biolabs) and ligated into pQCXIP digested with SbfI-HF (New England Biolabs) and PacI. BORF2 truncation mutants were generated by subcloning portions of pcDNA4-BORF2-3 × FLAG using high-fidelity PCR, digesting the PCR products with EcoRV-HF and NotI-HF, and ligating into pcDNA4-3 × FLAG as described earlier. The PCR primers are as follows: N-terminal BORF2 25-826 mutant (RSH14011 5′ -NNN NGA TAT CGC CAC CAT GTC AGA CCC CGA GGC TGA TGT C-3′ and RSH12848); BORF2 50-826 (RSH14012 5′ -NNN NGA TAT CGC CAC CAT GGC CGA ATA TCT GGA GGT CTT C-3′ and RSH12848); C-terminal BORF2 1-739 mutant (RSH12971 and RSH13396 5′ -NNN NGC GGC CGC TCC ATC ACC CCC AGA TCG GCG GC-3′ ); and BORF2 1-687 (RSH12971 and RSH13612 5′ -NNN NGC GGC CGC ACA AAG GGG GCC CTG TCC C-3′ ). BORF2 catalytic mutants were generated in pcDNA4-BORF2-3 × FLAG by site-directed mutagenesis using PfuUltra II Fusion HS DNA polymerase (Agilent) with the following primers for YY725/6AA (RSH13776 5′ -GGC CTG AAG ACT ATC ATG GCG CTT TGT CGC ATT GAG AAG GC-3′ and RSH13777 5′ -GCC TTC TCA ATG CGA CAA AGC GCC ATG ATA GTC TTC AGG CC-3′ ) and YY725/6FF (RSH13774 5′ -GGC CTG AAG ACT ATC ATG TTC TTT TGT CGC ATT GAG AAG GC-3′ and RSH13775 5′ -GCC TTC TCA ATG CGA CAA AAG AAC ATG ATA GTC TTC AGG CC-3′ ).
BaRF1 (GenBank accession number V01555.2) with C-terminal 3 × HA-tag (YPYDVPDYA) was cloned using high-fidelity PCR from a gBlock purchased from Integrated DNA Technologies using primers RSH13621 5′ -NNN NGA ATT CGC CGC CAC CAT GTC CAA GTT G-3′ and RSH13622 5′ -NNN NCT CGA GAA GGT CAT CTA CCA CCA GCA T-3′ . The PCR products were digested with EcoRI-HF (New England Biolabs) and XhoI (New England Biolabs) and cloned into pcDNA3.1 (+) (Thermo Fisher Scientific) with a C-terminal 3 × HA-tag.
The original pLentiCRISPR 42 vector, which was a gift from Feng Zhang (Addgene plasmid), was modified to improve gRNA expression and introduce a loxP site into the viral 3′-long terminal repeat (pLentiCRISPR-loxP; Carpenter et al., manuscript in preparation). A guide RNA (gRNA) targeting BORF2 was designed using crispr.mit.edu with a protospacer adjacent motif site of AGG at + 119 and predicted cut site at + 122 on the antisense strand (relative to the BORF2 start codon). gRNA primers (RSH13690 5′ -CAC CGG TGT AAC TGA
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CTC GGC CTT A-3′ and RSH13691 5′ -GAA CTA AGG CCG AGT CAG TTA CAC C-3′ ) were annealed, cut with BsmBI, and ligated into similarly digested pLentiCRISPR-loxP.
UGI (GenBank accession number: J04434.1) was amplified with high-fidelity polymerase from pcDNA3.1 (+) -UGI 43 using primers RSH7505 5′ -NNN NCT CGA  GAC CAT GAC AAA TTT ATC TGA CAT CAT TG-3′ and RSH7506 5-NNN  ACG CGT TTA TAA CAT TTT AAT TTT ATT TTC TCC-3′ , digested with XhoI  and MluI-HF, and ligated into similarly digested pLenti4/TO (Thermo Fisher  Scientific) . EBV UDG (BKRF3) (GenBank accession number: MG021307.1) was amplified with a high-fidelity polymerase from AGS-EBV(Bx1g) genomic DNA using primers RSH15814 5′ -GAA GCT TGG TAC CAT GGC ATC GCG GG-3′ and RSH15815 5′ -TCT AGA CTC GAG CTA CAG CCT CCA ATC-3′ , followed by restriction digest with KpnI-HF (New England Biolabs) and XhoI, and ligation into similarly digested pcDNA3.1/V5 44 . A gRNA targeting human UDG (UNG2) was designed using crispr.mit.edu with a protospacer adjacent motif site of TGG at + 274 and predicted cut site at + 271 on the sense strand (relative to the UNG2 start codon). gRNA primers (RSH11189 5′ -CAC CGC GCG GCC CGC AAC GTG CCC G-3′ and RSH11190 5′ -GAA CCG GGC ACG TTG CGG GCC GCG C-3′ ) were annealed, cut with BsmBI, and ligated to similarly digested pLentiCRISPR-loxP.
All RNR large subunit homologues were cloned into the previously described pCMV-3F plasmid 45 . Human RRM1 (GenBank accession number: BC006498) was amplified using high-fidelity PCR from a plasmid provided by the SPARC BioCentre using primers 5′ -GTA CGA GCT CGC CAC CAT GCA TGT GAT CAA GCG AGA TGG-3′ and 5′ -GAC TTC TAG AGG ATC CAC ACA TCA GAC ATT CAT C-3′ , digested with SacI (New England Biolabs) and XbaI (New England Biolabs), and ligated into similarly digested pCMV-3F. KSHV ORF61 46 (GenBank accession number: U75698.1) was kindly provided by Britt Glausinger (University of California, San Francisco), amplified using 5′ -GTA CAG ATC TGC CAC CAT GTC TGT CCG GAC ATT TTG-3′ and 5′ -GAC TTC TAG ACT GAC AGA CCA GGC ACT CG-3′ , digested with BglII and XbaI (New England Biolabs), and ligated into similarly digested pCMV-3F. Herpes simplex virus type 1 UL39 (GenBank accession number JN555585.1) was amplified from a library described previously 39 using primers 5′ -GAC TGA ATT CGC CAC CAT GGC CAG CCG CCC AGC-3′ and 5′ -GCA TTC TAG ACA GCG CGC AGC TCA TGC-3′ , digested with EcoRI (New England Biolabs) and XbaI, and ligated into similarly digested pCMV-3F. HCMV UL45 (GenBank accession number: FJ527563.1) was amplified from a library described previously 39 . The Akata EBV strain was engineered previously to express neomycin resistance 47 and GFP 19 . The neomycin-resistant Akata EBV strain was introduced previously into AGS cells to yield the AGS-EBV; the neomycin-resistant, GFP-expressing virus was used to derive the AGS-EBV(Bx1g) line used in the current study 14, 15, 19 . Akata EBV-containing cell cultures were additionally supplemented with 0.4 mg ml −1 G418 (geneticin). B cells transformed with the M81 EBV strain 18 were a gift from Henri-Jacques Delecluse (German Cancer Research Centre (DKFZ)) and were cultured in RPMI. This EBV strain spontaneously reactivates to the EBV lytic cycle without external treatment. Cells transduced with shCtrl or shA3B lentivirus were selected with 5 µ g ml −1 blasticidin S (Gold Biotechnology). Cells transduced with pLentiCRISPR targeting BORF2 or pQCXIP-BORF2 complementation lentiviruses were selected with 1 µ g ml −1 puromycin. Cells transduced with pLenti/TR to express tetracycline repressor (TR) were selected with 5 µ g ml −1 blasticidin S.
Affinity purification and mass spectrometry. Five 10 cm dishes of HEK293T cells were transfected with 6 μ g of PMZS3F-BORF2 39 using PolyJet at a 1:2 ratio; 48 h after transfection cells were collected and pooled. Cells were washed twice in PBS followed by lysis (50 mM Tris pH 7.9, 420 mM NaCl, 10% glycerol, 0.1% NP-40, protease inhibitors (P8340; Sigma-Aldrich), 1 mM NaF). Lysates were subjected to three cycles of freeze-thaw followed by sonication. Benzonase (25 U ml −1 ; Sigma-Aldrich) was added to the lysate and incubated on ice for 30 min. Lysates were then cleared by centrifugation (15,000 r.p.m.) in a table top microcentrifuge for 30 min. Cleared lysate was then added to 50 μ l of anti-FLAG M2 resin (Sigma-Aldrich) followed by end-over-end rotation for 3 h at 4 °C. Following immunoprecipitation, the anti-FLAG resin was washed twice in lysis buffer, followed by three additional washes in lower-salt, detergent-free wash buffer (10 mM Tris pH 7.9, 150 mM NaCl, 10% glycerol). Protein was eluted from the resin with three washes of 0.5 M ammonium hydroxide (15 min each at 25 °C with rotation). Samples were lyophilized in a SpeedVac (Savant DNA120; Thermo Fisher Scientific) and washed with 400 μ l HPLC-grade water (Gibco). Samples were lyophilized once more to remove traces of ammonium hydroxide, and then subjected to trichloroacetic acid precipitation, tryptic digestion, and tandem mass spectrometry (MS/MS) as described 48 . RAW files were submitted for database searching using X! TANDEM (v2007.07.01.3) and Trans-Proteomic Pipeline (version 4.3) under standard workflow and a modified UniProt/Swiss-Prot protein database FASTA file. The modification consisted of adding BSA (Swiss-Prot accession number P02769). Search parameters were set to allow for two missed cleavage sites, variable modification by methionine oxidation, and one fixed modification by cysteine carbamidomethylation. A 10 ppm filter was used for peptide identification. The search results were uploaded to ProHits 49 and compared using at least 99% Trans-Proteomic Pipeline probability.
RNA isolation, cDNA synthesis and RT-qPCR. RNA isolation, cDNA synthesis, and qPCR primers were described previously 50 . In brief, RNA was collected from 2 × 10 6 cells using the High Pure RNA Isolation Kit (Roche Molecular Systems); cDNA libraries were generated with reverse transcriptase (Roche Molecular Systems); and qPCR was performed on a LightCycler 480 instrument (Roche Molecular Systems). The housekeeping gene TBP was used for normalization.
Co-immunoprecipitation experiments and immunoblots.
Semi-confluent HEK293T cells were grown in 6-well plates and transfected with plasmids and 0.6 µ l TransIT-LT1 (Mirus) per 100 ng DNA in 100 µ l serum-free Opti-MEM reduced serum medium (Thermo Fisher Scientific). In most experiments, 100 ng DNA was used for each unique plasmid transfection (for example, Fig. 1b ,c-f and Supplementary Figs. 3 and 4 ). For the A3 panel and RNR homologue co-immunoprecipitation experiments ( Fig. 1c and Supplementary  Fig. 2a ), a titration series was performed to achieve roughly equivalent protein expression by immunoblot. Growth medium was removed after 48 h and whole cells were collected in 1 ml PBS-EDTA by pipetting. Cells were spun down, PBS-EDTA was removed, and cells were resuspended in 300 µ l of ice-cold lysis buffer (150 mM NaCl, 50 mM Tris-HCl, 0.5% Tergitol, and Roche cOmplete EDTA-free protease inhibitor cocktail tablet (Sigma-Aldrich), pH 7.4). Cells were vortexed vigorously and left on ice for 30 min, then sonicated for 5 s in an ice water bath; 30 µ l of whole cell lysate was aliquoted for immunoblot. Lysed cells were spun down at 13,000 r.p.m. for 15 min to pellet debris and supernatant was added to the clean tube with 25 µ l resuspended anti-FLAG M2 Magnetic Beads (Sigma-Aldrich) for overnight incubation at 4 °C with gentle rotation. Beads were then washed three times in 700 µ l of ice-cold lysis buffer. Bound protein was eluted in 30 µ l of elution buffer (0.15 mg ml −1 FLAG peptide (Sigma-Aldrich) in 150 mM NaCl, 50 mM Tris-HCl, 0.05% Tergitol, pH 7.4). Proteins were analysed by immunoblot; the antibodies used included mouse monoclonal anti-FLAG 1:5,000 (Sigma-Aldrich), mouse monoclonal anti-BORF2 1:1,000 (Santa Cruz Biotechnology), mouse anti-BZLF1 1:3,000 (Santa Cruz Biotechnology), mouse monoclonal anti-α -tubulin 1:10,000 (Sigma-Aldrich), mouse anti-β -actin 1:10,000 (Santa Cruz Biotechnology), rabbit monoclonal anti-HA-tag 1:3,000 (Cell Signalling), rabbit polyclonal anti-Strep-tag II 1:5000 (Abcam), and rabbit anti-A3B 1:1,000 (5210-87-13 36 ).
Protein purification from E. coli and DNA deaminase activity assays. pE-6xHis-SUMO-A3Bctd 187-378 -DM (L230K/F308K) 51 and pE-6xHis-SUMO A3H Hap II 1-183 52 have been reported previously for E. coli expression and protein purification. Codon-optimized BORF2 was synthesized by Bio Basic, digested with BsmBI (New England Biolabs), and ligated into pE-6xHis-SUMO (LifeSensors) for E. coli expression and protein purification. CaCl 2 -competent BL21(DE3) E. coli were transformed, grown overnight on lysogeny broth-kanamycin plates, and single-cell colonies were inoculated in 1 l 2× YT media with 50 µ g ml −1 kanamycin and grown at 37 °C until ~A 600 nm = 0.8. Cells were then induced with 0.5 mM isopropyl-β -D-thiogalactoside and grown at 16 °C overnight for protein expression. Cells were centrifuged and resuspended in 30 ml of ice-cold lysis buffer (300 mM NaCl, 50 mM Tris-HCl, 20 mM imidazole, 200 µ g ml −1 RNase A, 100 µ g ml −1 lysozyme, cOmplete EDTA-free protease inhibitor, pH 7.4). Cells were incubated on ice for 30 min, then lysed by pulse sonication twice for 2 min in an ice water bath (Branson Sonifer). Lysed cells were spun down at 13,000g for 30 min to remove debris. The supernatant was added to 2 ml of Ni-NTA agarose beads (QIAGEN) and incubated at 4 °C for 30 min with gentle rocking. Beads were then washed twice with 10 ml of wash buffer (300 mM NaCl, 50 mM Tris-HCl, 40 mM imidazole, pH 7.4). Bound protein was eluted twice with 500 µ l of elution buffer (300 mM NaCl and 250 mM imidazole).
Recombinant purified proteins were mixed with 2× reducing sample buffer (100 mM Trish-HCl pH 6.8, 20% glycerol, 4% SDS, 5% β -mercaptoethanol, 0.05% bromophenol blue), run on 4-20% SDS-polyacrylamide gel electrophoresis (PAGE) gels, stained with Coomassie Brilliant Blue stain (40% methanol, 10% acetic acid, 0.1% Coomassie R-250), then quantified by densitometric analyses on ImageJ (https://imagej.nih.gov/ij/) using BSA as a standard. A3 proteins were titrated to Letters NATuRE MICROBIOlOGy achieve equivalent enzymatic cleavage of a fluorescent oligo substrate (RSH5194 5′ -ATT ATT ATT ATT CAA ATG GAT TTA TTT ATT TAT TTA TTT ATT T-fluorescein-3′ ) by mixing together 1 µ l recombinant A3, 1 µ l 10.7 µ M oligo, 0.5 µ l 1 mg ml −1 RNase, 0.025 µ l UDG (New England Biolabs), and 7.47 µ l modified 2-hydroxyethyl disulfide (HED) buffer (20 mM HEPES, 50 mM NaCl, 0.1 mM EDTA, 0.1 mg ml −1 BSA, pH 7.4) and incubating at 37 °C for 30 min; 1 µ l of 1.1 M NaOH (100 mM final) was then added and heated to 98 °C for 5 min to cleave the DNA at abasic sites. The reaction was then mixed with 11 µ l 2× formamide buffer (80% formamide, 1× Tris/borate/EDTA (TBE), bromophenol blue, and xylene cyanol) and run on a 15% TBE-urea PAGE gel. Separated DNA fragments were visualized on a Typhoon FLA 7000 scanner on fluorescence mode (GE Healthcare). A3 deaminase activity was quantified by densitometric analyses on ImageJ by dividing product band intensity by the sum of product and substrate band intensities. Approximately equivalent deaminase activity was achieved at 350 nM A3Bctd and 80 nM A3H. Recombinant proteins were then diluted to specified concentrations in HED buffer; 5 µ l of recombinant BORF2 was equilibrated with 2 µ l of A3 proteins for 15 min and added to 3 µ l of an oligo master mix containing 1 µ l of 10.7 µ M fluorescent oligo, 0.5 µ l 1 mg ml −1 RNase, 0.025 µ l UDG (New England Biolabs), and 1.475 µ l HED buffer for a total reaction volume of 10 µ l, which was incubated at 37 °C for 30 min. The deaminase activity assay then proceeded as stated earlier.
Normalized percentage A3 deaminase activity was calculated for n = 3 independent biological replicates by defining 100% deaminase activity as the no BORF2 condition for both A3Bctd and A3H. Normalized percentage activities were averaged and standard deviations were calculated. Assuming normal data distributions, one-tailed one sample t-tests were performed at each concentration of BORF2 to determine if mean A3Bctd or A3H deaminase activity differed from the null hypothesis µ = 1 (100% activity) with the alternative hypothesis µ < 1, d.f. = 2. P values for A3Bctd are as follows for the following concentrations of BORF2: P = 0.0237 at 43.75 nM; P = 0.00206 at 87.5 nM; P = 9.56 × 10 −5 at 175 nM; P = 2.51 × 10 −6 at 350 nM; P = 2.685 × 10 −5 at 700 nM). P values for A3H are P = 0.970 at 43.75 nM; P = 0.816 at 87.5 nM; P = 0.424 at 175 nM; P = 0.440 at 350 nM; P = 0.1575 at 700 nM.
MG132 experiments. Semi-confluent HEK293T cells were transfected with 100 ng of each indicated plasmid and 1.8 µ l TransIT-LT1 transfection reagent in 100 µ l serum-free Opti-MEM in 6 wells. After 42 h post-transfection, media was removed and replaced with fresh media containing 10 µ M MG132 (Sigma-Aldrich) or dimethylsulfoxide control. Cells were collected after 4 h of MG132 treatment, washed twice with PBS, and analysed by immunoblot. Antibodies used included rabbit polyclonal anti-c-Myc 1:3,000 (Sigma-Aldrich), rabbit anti-HA, mouse anti-FLAG 1:5,000, and mouse anti-tubulin 1:10,000.
Immunofluorescence microscopy. For immunofluorescence imaging of endogenous proteins, AGS-EBV or BORF2-null AGS-EBV cells were grown on acidwashed and poly(lysine)-treated 22 × 22 × 1.5 mm 3 coverslips (Fisherbrand, Thermo Fisher Scientific) until they reached 80% confluency. Cells were either left untreated (latent infection samples) or treated with 20 ng ml −1 TPA and 3 mM sodium butyrate (NaB) for 8, 16, or 24 h to reactivate the virus into the lytic cycle. Coverslips were then washed with PBS, fixed in 4% methanol-free formaldehyde (Thermo Scientific Scientific) for 15 min, and rinsed three times for 5 min in PBS with gentle rocking. Cells were permeabilized with 0.2% Triton X-100 in PBS for 10 min, washed three times for 5 min in PBS, then blocked overnight in 5% BSA. Cells were incubated with rabbit anti-A3B 1:1,000 (5210-87-13) 36 and mouse anti-BORF2 1:400 (Santa Cruz Biotechnology) in AGS-EBV cells, or mouse monoclonal anti-BMRF1 1:400 (Merck Millipore) in BORF2-null AGS-EBV cells to indicate reactivated cells for 48 h in a humid chamber at 4 °C. Coverslips were washed three times with PBS, followed by incubation with secondary antibodies, goat anti-rabbit polyclonal Alexa Fluor 488 1:1,000 (Thermo Fisher Scientific) or donkey anti-mouse polyclonal Alexa Fluor 647 1:1,000 (Thermo Fisher Scientific) in 5% BSA for 1 h. After washing in PBS, coverslips were mounted onto slides using ProLong Gold antifade mountant (Thermo Fisher Scientific) containing 4′ ,6-diamidino-2-phenylindole. Images were captured using the 40× oil objective on a Leica inverted fluorescence microscope and analysed with the Leica Application Suite X (version 3.3.0) software. For each TPA/NaB-treated sample, 50 reactivated cells were analysed for colocalization of BORF2 and A3B. For latent AGS-EBV cells and reactivated cells containing the BORF2 knockout virus, the overall localization of A3B was scored for 50 cells. For immunofluorescence of M81 cells, approximately 5 × 10 6 cells were collected during log-phase growth. The immunofluorescence protocol then proceeded as stated earlier except for permeabilization in 0.5% instead of 0.2% Triton X-100 and primary antibody incubation for 24 h in constant rotation at 4 °C.
For EdU staining of AGS-EBV, cells were grown on coverslips until they reached 80% confluency. Cells were then treated with 10 µ M EdU (Thermo Fisher Scientific) for 1 h before collection and fixed in 4% formaldehyde followed by washing in PBS, permeabilization in 0.5% Triton X-100, and blocking in 5% BSA for 1 h. Staining of EdU was done according to the manufacturer's protocol. Cells were incubated with rabbit anti-A3B 1:1,000 (5210-87-13) 36 and mouse monoclonal anti-BMRF1 (Merck Millipore) 1:1,000 antibody for 48 h in a humid chamber. The immunofluorescence protocol then proceeded as stated earlier.
For immunofluorescence imaging of transfected cells, HEK293T, HeLa, or AGS cells were plated on coverslips and, after 24 h, transfected with 200 ng pcDNA4-BORF2-3xFLAG, 200 ng pcDNA5/TO-A3B-eGFP, or both. After 48 h, cells were collected, fixed in 4% formaldehyde, and permeabilized in 0.2% Triton X-100 as stated earlier. Cells were then incubated in blocking buffer (0.0028 M KH 2 PO 4 , 0.0072 M K 2 HPO 4 , 5% Gibco goat serum (Thermo Fisher Scientific), 5% glycerol, 1% cold water fish gelatin (Sigma-Aldrich), 0.04% sodium azide, pH 7.2) for 1 h. Cells were then incubated in blocking buffer with primary mouse anti-FLAG 1:1,000 antibody for 2 h to detect BORF2-FLAG. Cells were washed three times for 5 min with PBS then incubated in secondary antibodies diluted in blocking buffer for 1 h at room temperature with goat anti-mouse Alexa Fluor 594 1:1,000 antibody in the dark. Cells were then counterstained with 1 µ g ml −1 Hoescht 33342 for 10 min, rinsed twice for 5 min in PBS, and once in sterile water. Coverslips were mounted on pre-cleaned slides (Gold Seal Rite-On; Thermo Fisher Scientific) using one drop (10-15 µ l) of mounting medium (dissolve 1 g n-propyl gallate (Sigma-Aldrich) in 30 ml glycerol overnight, add 0.35 ml 0.1 M KH 2 PO 4 , then pH to 8-8.5 with K 2 HPO 4 , quantum satis to 50 ml with water). Slides were imaged on a Nikon Inverted Ti-E Deconvolution Microscope and analysed with NIS Elements (Nikon).
For the KSHV ORF61 experiments, HEK293T and AGS cells were transfected with 500 ng pcDNA5/TO-A3B-eGFP, 500 ng pCMV3F-ORF61, or both. After 48 h, cells were collected, fixed in 3.7% formaldehyde, and permeabilized in 0.2% Triton X-100 as stated earlier. Cells were then blocked in 5% BSA and incubated for 1 h. Cells were then incubated with mouse anti-FLAG 1:1,000 antibody for 2 h; then, the immunofluorescence protocol proceeded as stated earlier. Cell images were taken with a Leica inverted fluorescence microscope and analysed with the Leica Application Suite X software.
For the live cell imaging experiments, HEK293T cells were transfected with pLenti6/TR (Thermo Fisher Scientific), gag/pol polyprotein, and vesicular stomatitis virus G (VSV-G) protein to produce lentivirus-expressing TR. Other HEK293T cells were transfected with MLV-based pQCXIP-BORF2-eGFP, MLV gag/pol polyprotein, and VSV-G to produce lentiviral expression for BORF2-eGFP transduction. U2OS cells were first transduced with pLenti6/TR; after 48 h, the virus was washed off and cells were selected with 5 µ g ml −1 blasticidin S for 2 weeks. Limiting dilution was used to generate single-cell clones and screened for TR expression and gene repression. U2OS-TR cells were then transfected with pcDNA5/TO-A3B-mCherry and put under 200 µ g ml −1 hygromycin selection. After 2 weeks, the limiting dilution was used to generate a second generation of singlecell clones and screened. U2OS-TR-A3B-mCherry cells were plated on coverslips in 6-well plates for live cell imaging. A3B-mCherry expression was induced after 24 h with 10 ng ml −1 doxycycline, and then transduced with pQCXIP-BORF2-eGFP lentivirus 24 h after induction. One hour after transduction, cells were imaged on a Nikon BioStation IM machine every 15 min for 48 h. Images were analysed and stitched into a movie using NIS Elements. In the reciprocal experiment, U2OS-TR-A3B-mCherry cells were plated and transduced with pQCXIP BORF2-eGFP; after 24 h, they were induced with 10 ng ml −1 doxycycline. Image acquisition began 1 h after A3B-mCherry induction as previously stated.
For immunofluorescence imaging of BiP, U2OS-TR-A3B-mCherry cells were plated on coverslips and induced with 10 ng ml −1 doxycycline for A3B-mCherry expression and transduced with pQCXIP-BORF2-eGFP lentivirus. After 48 h, cells were fixed and blocked as stated earlier and stained with rabbit polyclonal anti-GRP-78 BiP 1:1,000 antibody (Abcam) overnight to detect the endoplasmic reticulum. Cells were washed three times for 5 min each with PBS then incubated in goat anti-rabbit Alexa Fluor 647 1:1,000 diluted in blocking buffer for 1 h at room temperature in the dark. The immunofluorescence protocol then proceeded as stated earlier for the transfected proteins. Slides were imaged on a Nikon Inverted Ti-E Deconvolution Microscope and analysed with NIS Elements, including deconvolution of images. For 3D reconstruction of the endoplasmic reticulum experiments, z-stacks were captured every 0.6 μ m throughout the entire cell depth. Deconvolution was performed for each z-stack; then, a movie of the 3D reconstruction was generated using NIS Elements (Supplementary Video 1) . For endoplasmic reticulum colocalization with TRAPα , reactivated AGS-EBV cells were stained with primary mouse anti-BORF2 1:400 antibody, rabbit anti-TRAPα 1:1,000 antibody, or both for 1 h (gift from Alexander Palazzo 53 ); then, the immunofluorescence protocol proceeded as stated earlier. z-stacks were captured every 0.3 μ m throughout the entire cell depth and stitched together into a z-series movie (Supplementary Video 2).
Generation of BORF2-null EBV with CRISPR-Cas9. gRNAs targeting BORF2 were generated using the CRISPR Design Tool (http://crispr.mit.edu/). Oligonucleotides were purchased from Integrated DNA Technologies and cloned into a pLentiCRISPR-loxP vector (see DNA constructs section). HEK293T cells were transfected with pLentiCRISPR, gag/pol polyprotein, and VSV-G. The supernatant containing the knockout lentivirus was collected after 48 h and used to transduce AGS-EBV, AGS-EBV(Bx1g), or Akata B cells. After 48 h, lentivirus was washed off and cells were subjected to antibiotic selection with media supplemented with 1 µ g ml −1 puromycin for 4 weeks. Pooled cells were screened for successful BORF2 knockout from EBV genomes by immunoblot with mouse anti-BORF2 1:1,000 antibody. Sanger sequencing was completed on viral genomic DNA collected from BORF2-null AGS-EBV(Bx1g) cells ( Supplementary Fig. 4 ).
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To generate a clonal AGS cell line with isogenic BORF2-null EBV(Bx1g), described in this article as AGS-EBV(Bx1g)∆ BORF2, pooled cells were supplemented with exogenous deoxy-nucleoside monophosphates (dAMP/dCMP/ dGMP/dTMP, each 400 µ M) for 72 h and then induced with 3 mM sodium butyrate and 20 ng ml −1 TPA to produce EBV particles. After 48 h, the virus-containing supernatant was collected, filtered, and ultra-centrifuged at 22,000 r.p.m. for 2 h to obtain the concentrated cell-free, BORF2-null EBV stock. This virus stock was used to infect non-EBV-infected AGS cells at various empirically determined dilutions. Virus was washed off after 48 h and AGS cells were subjected to antibiotic supplementation with 0.4 mg ml −1 G418 for 2 weeks to select for successful EBV infection. These EBV-infected AGS cells were split into 96-well plates to obtain single-cell colonies by limiting dilution. Colonies were then screened for BORF2null virus infection by immunoblot. Knockout clones were screened for successful isogenic EBV infection using Sanger sequencing (n > 10 sequences per clone). The isogenic AGS-EBV(Bx1g)∆ BORF2 clone used in the current study has a 1,426 bp deletion spanning nucleotides + 88 to + 1,514 relative to the start codon.
Complementation, shRNA knockdown, and UGI experiments. HEK293T cells were transfected with MLV-based pQCXIP-BORF2-FLAG or empty pQCXIP vector, MLV gag/pol polyprotein, and VSV-G to produce complementation lentivirus. Other HEK293T cells were transfected with pLKO constructs expressing A3B-targeting shRNA or control non-targeting shRNA, gag/pol polyprotein, and VSV-G to produce knockdown lentivirus. Other HEK293T cells were transfected with pLenti4-UGI or empty pLenti4 vector, gag/pol polyprotein, and VSV-G to produce UGI lentivirus.
The AGS-EBV(Bx1g)∆ BORF2 clone was first transduced with BORF2 or control complementation lentivirus. After 48 h, virus was washed off and cells were selected with 1 µ g ml −1 puromycin for 2 weeks. These cells were then transduced with either A3B or control knockdown lentivirus. After 48 h, virus was washed off and cells were selected with 5 µ g ml −1 blasticidin S for 2 weeks. These cells were then transduced with either UGI or control treatment lentivirus; 48 h after transduction, virus was washed off and split into two arms for either virus induction with TPA/NaB or mock induction. After 48 h of lytic reactivation, DNA and protein were collected and analysed by 3D-PCR or immunoblot, respectively.
Generation of AGSΔUNG2 cell line with CRISPR-Cas9
. gRNAs targeting human UNG2 were generated using the CRISPR Design Tool. Oligonucleotides were purchased from Integrated DNA Technologies and cloned into a pLentiCRISPR-loxP vector. HEK293T cells were transfected with pLentiCRISPR-loxP, gag/pol polyprotein, and VSV-G. The supernatant containing the knockout lentivirus was collected after 48 h and used to transduce AGS cells. After 48 h, lentivirus was washed off and cells were subjected to antibiotic selection with media supplemented with 1 µ g ml −1 puromycin for 2 weeks. Limiting dilution was then used to generate single-cell clones, which were screened for successful UNG2 knockout by immunoblot and UDG (BKRF3) activity. Antibodies used included rabbit anti-UNG2 1:1,000 (gift from Sal J. Caradonna, Rowan University) and antitubulin 1:10,000. UDG activity assays. AGS or AGSΔ UNG cells were transfected with 1 µ g BKRF3 or vector control using 3 µ l TransIT-LT1 in serum-free RPMI. Cells were collected after 30 h and lysed in 300 µ l modified HED buffer (20 mM HEPES, 15 mM EDTA, cOmplete EDTA-free protease inhibitor cocktail tablet, pH 7.4) per 10 6 cells. Activity assays were carried out as described 12 using a 10 min incubation with a dU-containing oligonucleotide (RSH12955 5′ -AAA AAA AAA UCG GGA AAA AAA-fluorescein-3′ ); 2 µ l of UGI (4 units; New England Biolabs) were used to inhibit UDG. Products were separated by a 20% TBE-Urea PAGE. Separated DNA fragments were visualized on a Typhoon FLA 7000 scanner on fluorescence mode.
3D-PCR and sequencing.
Total genomic DNA was collected from cells using the Gentra Puregene Cell Kit (QIAGEN). Genomic DNA was used as a template for first-round PCR with ChoiceTaq DNA polymerase (Denville) using the manufacturer's protocol with primers for BRRF2 (5′ -GTA GCA TCT CTG TCT GGT GAC CTT GAA-3′ and 5′ -TTT TGG GGT CTC CGG ACA CCA TCT CTA-3′ ) and EBNA2 (5′ -TAA CGT GCA AGA CGC TAA ACT TAA CCA A-3′ and 5′ -AGC CTC GGT TGT GAC AGA GGT GAC AA-3′ ). First-round PCR products were run on a 3% agarose gel by gel electrophoresis, normalized by densitometry, and then used for second-round PCR. Second-round PCR used Phusion High-Fidelity DNA Polymerase (New England Biolabs) using primers for BRRF2 (5′ -AGG CCT GGC TTG AGG CTC AGG ACG CAA-3′ and 5′ -GAC ATG ATT CAC ACT AAA AGA GAT CAA-3′ ) and EBNA2 (5′ -ACA ATC TTT GTT GGG GAA AAC ACG GGG G-3′ and 5′ -CGT CAT ATC CTA GCG GAT CCC TAT CAA-3′ ). The following PCR conditions were used for BRRF2 (87-91 °C melting, 60 °C annealing, 72 °C extension) and EBNA2 (84-88 °C melting, 60 °C annealing, 72 °C extension). Second-round PCR products were run on a 3% agarose gel and the lowest-temperature PCR amplicons were gel-extracted with the GeneJET Gel Extraction Kit (Thermo Fisher Scientific), blunt-end cloned with the CloneJET PCR Cloning Kit (Thermo Fisher Scientific), and transformed into CaCl 2 -competent DH10B E. coli. Single-cell colonies were picked for colony PCR using Phusion High-Fidelity DNA polymerase with the primers provided by the manufacturer (5′ -CGA CTC ACT ATA GGG AGA GCG GC-3′ and 5′ -AAG AAC ATC GAT TTT CCA TGG CAG-3′ ). PCR products were enzymatically purified using Exonuclease I (E. coli; New England Biolabs) and shrimp alkaline phosphatase (New England Biolabs) treatment. Sanger sequencing of purified PCR products used the 5′ -AAG AAC ATC GAT TTT CCA TGG CAG-3′ primer, sequenced by GENEWIZ (https://www.genewiz.com/), and results were analysed with the SnapGene software (http://www.snapgene.com/). A3B genotyping. The PCR breakpoint assay to identify WT versus the 29.5 kb A3B deletion genotype was previously described 26 . Briefly, PCR primers within the A3B gene (blue arrows in Supplementary Fig. 13b ) generate a 490 bp PCR product while the primers flanking the A3A/B fusion (red arrows in Supplementary Fig. 13b ) generate a 700 bp PCR product.
Deep-sequencing analysis. The AGS-EBVΔ BORF2 clone was complemented with a mock vector or BORF2-FLAG, and transduced with shCtrl or shA3B lentivirus. Genomic DNA was collected from cells 3 days after induction with TPA/NaB and portions of the EBV genome were PCR-amplified using PfuTurbo Hotstart DNA Polymerase (Agilent). The PCR products correspond to regions near the genes BRRF2 (95085-95584), LMP1 (167979-168514), BHRF1 (42090-42595), and BcLF1 (124082-124598). Base numbers correspond to the Akata reference genome (GenBank accession number: KC207813), which was also used for both the assembly and variant calling described later. Primers were designed with Nextera-compatible adapter sequences: forward 5′ -TCG TCG GCA GCG TCA GAT GTG TAT AAG AGA CAG-[locus-specific]-3′ and reverse 5′ -GTC TCG TGG GCT CGG AGA TGT GTA TAA GAG ACA G-[locus-specific]-3′ . Locusspecific primers were designed as follows: BRRF2 (RSH15191 5′ -ACC GTC CAG CAA AAA GGG-3′ and RSH15192 5′ -CCC CTT TGC AGC CAA TGC-3′ ); LMP1 (RSH15195 5′ -CTG CCA CAC TAC CCT GAC-3′ and RSH15196 5′ -AGC CGC CAG AGA ATC TCC-3′ ); BHRF1 (RSH15205 5′ -GTG TTG GAG CTA GCA GCA AGA G-3′ and RSH15206 5′ -CCG CAG GCC CAA TGA CCC-3′ ); and BcLF1 (RSH15207 5′ -CCT GCT GGT GGG CAA GGA-3′ and RSH15208 5′ -AGA TGC CTC TTG AAC ATG GC-3′ ). The PCR products were enzymatically purified using Exonuclease I and shrimp alkaline phosphatase treatment.
Illumina amplicon sequencing was performed at the University of Minnesota Genomics Center as a ≥ 16 million read, 2 × 300 bp paired-end MiSeq v3 run. Sequences were aligned and assembled with the Burrows-Wheeler Aligner 54 , GATK toolkit 55 , Picard Tools (http://broadinstitute.github.io/picard/), and SAMtools 56, 57 . VarScan2 58 was used to call variation compared to the Akata reference genome. SAMtools and R (http://www.R-project.org) were used for subsequent read and sequence filtering, processing, and visualization. Viral infectivity assays. AGS-EBV(Bx1g) or BORF2-null cells were plated on ten 15 cm plates, each at equal density, and grown until 70-80% confluency. Medium was then replaced with fresh RPMI containing 10% FBS, 1× penicillinstreptomycin, 20 ng ml −1 TPA, and 3 mM sodium butyrate to induce lytic reactivation (without G418). Cells were grown for 4 days and media was collected and centrifuged briefly to pellet cells; the resulting supernatant was passed through a 0.45 µ m filter (VWR). Filtered supernatant was centrifuged at 25,000 r.p.m. for 2.5 h using a Beckman Coulter JLA-16.250 rotor at 4 °C in a floor model centrifuge. The supernatant was then removed and the bottle walls were washed extensively with PBS to remove residual TPA/NaB, taking care not to disturb the visible viral pellet. The virus pellet was then resuspended in 1 ml RPMI with 10% FBS and 1× penicillin-streptomycin; 19 µ l concentrated virus was then mixed with 1 µ l DNase (QIAGEN) and incubated at 37 °C for 10 min followed by 10 min of heat inactivation at 98 °C. A quantity of 1 µ l DNase-treated virus was used to quantify viral titres in quadruplicate by RT-qPCR using a SsoFast EvaGreen Supermix (Bio-Rad) and the primer set for EBV gp350 (5′ -GTC AGT ACA CCA TCC AGA GCC-3′ and 5′ -TTG GTA GAC AGC CTT CGT ATG-3′ ). Known quantities of EBV B98.5 bacterial artificial chromosome DNA were used as a standard curve (gift from Ya-Fang Chiu, Chang Gung University). Equal titres of viral DNA were then used to infect 50,000 Ramos cells in 200 µ l in a 96-well plate. Fresh RPMI was used as mock infection. After 22 h, Ramos cells were collected, washed twice with PBS, resuspended in 200 µ l PBS-EDTA, and analysed by flow cytometry.
Akata or Akata BORF2-null cells were grown in 400 ml media until a confluency of ~1-2 × 10 6 cells ml −1 . Cells were pelleted and resuspended at a density of 4 × 10 6 cells ml −1 in 100 ml of RPMI with 10% FBS, 1× penicillinstreptomycin, and 6 µ g ml −1 goat anti-human serum immunoglobulin G fraction (MP Biomedicals) to induce lytic reactivation (without G418). After 2 days, the media volume was doubled with RPMI supplemented with 10% FBS and 1× penicillin-streptomycin. After 4 days post-induction, cells were briefly centrifuged to pellet cells; the resulting supernatant was passed through a 0.42 µ m filter. Filtered supernatant was treated in a similar fashion to the one already described for the virus produced from the AGS-EBV cells. All infectivity studies were performed with at least two independent biological replicates for virus production, each quantified by n = 3-4 independent reporter cell infections. 
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